Gapping up
In reaction to earnings/guidance:
- TLRY +19.4%, SCVL +12.9%, EXPR +9%, NCS +7.7%, LCI +3.6%, PSEC +2.4%, CHS +1.9%, HPE +1.3% (also announced that Tarek Robbiati has been appointed chief financial officer), MOV +0.8%
M&A news:
- EBS +2.4% (Emergent BioSolutions announces agreement to acquire Adapt Pharma and its flagship product NARCAN for total consideration of up to $735 mln in cash and stock)
Other news:
- GKOS +21.1% (Alcon (Novartis (NVS) unit) announced a voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma)
- BLDP +16.7% (entered into a strategic collaboration with Weichai Power Co)
- AFMD +15.3% (after closing the day up 247%)
- CRON +9.7% (following TLRY results)
- CGC +6.5% (following TLRY results)
- UIS +5.7% (to replace Marriott Vacations in S&P 600)
- LSCC +3.5% (plans to undertake search for new CFO; Max Downin will remain in his current role until co appoints successor)
- MFGP +3% (announces the commencement of a share buy-back programme with an initial tranche of up to $200 mln)
- CRH +2.2% (commences Phase 2 of buyback program)
- FANH +0.8% (increases share repurchase program from $20 mln to 6.5 mln ADS)
Analyst comments:
- DOVA +4.9% (initiated with a Outperform at Raymond James)
- RACE +2.5% (upgraded to Buy from Hold at HSBC Securities)
- RCL +1.5% (upgraded to Buy from Hold at Deutsche Bank)
- GOLD +0.9% (upgraded to Buy from Neutral at UBS)
- WTW +0.8% (initiated with Outperform rating and $98 tgt at Oppenheimer)
![]()